ProMIS Neurosciences (PMN) Moody Capital Disruptive Growth & Life Science Conference summary

Company overview and technology

• Focused on developing therapeutic antibodies for neurodegenerative diseases, including Alzheimer's, ALS, and Parkinson's disease.

• Technology targets misfolded proteins, using computational modeling to design antibodies that bind only to toxic forms, avoiding healthy proteins.

• Pipeline includes candidates for Alzheimer's (PMN310), ALS, and Parkinson's, with a differentiated approach compared to existing therapies.

• Publicly traded with recent financing of up to $175 million from top institutional investors.

• Leadership includes experienced neuroscience and clinical development professionals.

Clinical development and trial design

• Lead asset PMN310 is in a robust, placebo-controlled, double-blind phase I-B trial for early Alzheimer's, with 144 patients enrolled for 12 months of monthly dosing.

• Study design aims to provide definitive efficacy and safety data, with interim and final analyses planned.

• Fast Track designation granted by FDA due to significant unmet medical need.

• Interim blinded analysis conducted at six months to assess safety and biomarker changes.

• Subcutaneous formulation development and preparations for phase III registration study are underway.

Interim clinical results and safety profile

• Six-month interim analysis showed zero cases of ARIA-E (brain swelling) and no treatment-related serious adverse events or dropouts.

• Overall ARIA rates tracked with placebo, contrasting sharply with higher rates seen in approved drugs.

• Safety profile is especially favorable for high-risk APOE4 carriers, who are often excluded from current therapies.

• Biomarker analysis revealed a 15% reduction in p-tau217 and similar trends in MTBR-tau243, indicating strong target engagement.

• 68% of patients showed a decline in p-tau217, aligning with the study's randomization ratio.